http://www.theuknews.com/index.php/sid/239702893 The UK News Thursday 24th December, 2015 WASHINGTON - The US Drug Enforcement Administration (DEA) under a new policy has decided to ease requirements for conducting Food and Drug Administration (FDA) approved clinical trials on cannabidiol (CBD), an extract of the marijuana plant. The change aims to "streamline the research process regarding CBD's possible medicinal value and help foster ongoing scientific studies," DEA said in a release Wednesday. Earlier this month, researchers presented data showing CBD's promise in helping treat seizures in children with epilepsy and its use by thousands to alleviate symptoms associated with chemotherapy, wasting syndrome, AIDS, and a long list of other ailments. Essentially the move cuts through some of the red tape facing cannabis-related studies. Effective immediately, researchers in FDA-approved clinical trials can apply for a permit to possess an "approved amount" of cannabidiol for research, allowing research teams to obtain their supply more seamlessly.